

CANAKINUMAB

BRAND NAME	ILARIS
DRUG CLASS	Immunosuppressant, monoclonal antibody (human)
AVAILABILITY	Vial contains 150 mg of canakinumab. Also contains sucrose, histidine, histidine hydrochloride monohydrate, hydrochloric acid and polysorbate-80. ¹ <div style="border: 2px solid red; padding: 5px; margin-top: 10px;">The occupational hazard of intermittent low dose exposure to canakinumab is not known. Wear a mask and gloves when reconstituting the vial and preparing the injection to minimise exposure.</div>
pH	No information
PREPARATION	Reconstitute the vial with 1 mL of water for injections to make a concentration of 150 mg/mL. ¹ Swirl the vial gently and slowly at an angle of 45 degrees for about 1 minute then let stand for 5 minutes. Gently invert the vial 10 times then let stand for a further 15 minutes until the solution is clear to opalescent. Do not shake. ¹
STABILITY	Vial: store at 2 to 8 °C. Do not freeze. Protect from light. ¹ Reconstituted solution: stable for 60 minutes below 25 °C or 24 hours at 2 to 8 °C. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Suitable for children over 2 years and adults. ¹ Inject slowly into the abdomen, buttocks, upper arm or upper thigh. ^{1,2} Suitable for self-administration after appropriate patient education. ¹
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	No information
INCOMPATIBILITY	No information
SPECIAL NOTES	May cause redness, pain and itching at the injection site. ² Hypersensitivity reactions have been reported. ¹

REFERENCES

1. Product information. North Ryde, NSW: Novartis. Approved 10/05/2017. Updated 26/05/2017. Accessed 02/10/2019.
2. Consumer medicine information. North Ryde, NSW: Novartis; May 2017. Accessed 02/10/2019.